<DOC>
	<DOCNO>NCT00539188</DOCNO>
	<brief_summary>Self-Injurious Behavior ( SIB ) dangerous common symptom Borderline Personality Disorder ( BPD ) patient . Approximately 70 % patient BPD engage SIB point , compare 17.5 % patient personality disorder . While SIB may prompt unnecessary psychiatric hospitalization , may also cause potential underestimation lethality suicidal behavior , thus create major confuse challenge practice clinical psychiatry . Dialectical Behavioral Therapy ( DBT ) collection therapeutic technique focus emotional regulation , impulse control , improve safety patient BPD others mark self-destructive behavioral tendency . Though DBT mark ability reduce BPD symptomatology , include SIB , improvement SIB limit dependent extensive therapy time . Furthermore , literature pharmacological treatment SIB associate BPD scarce . Animal study suggest SIB may associate imbalance dopamine glutamate brain . Anti-seizure medication modulate glutamate transmission , lamotrigine topiramate , suggest effective treatment SIB human . Preliminary evidence suggest antiglutamatergic medication may decrease SIB patient BPD . Early study focus antiglutamatergic drug riluzole . More recently , become interested amino acid N-acetylcysteine ( NAC ) , use clinically antioxidant property widely available nutritional supplement . Recent animal study suggest NAC modulate glutamate central nervous system way similar propose riluzole , indeed observed NAC effect similar riluzole case treatment-refractory obsessive-compulsive disorder . This study double-blind , randomize , placebo-controlled evaluation N-Acetylcysteine adjunct DBT treatment SIB associate BPD . Subjects participate study recruit exclusively Dialectical Behavioral Therapy program Yale-New Haven Hospital , order maximize homogeneity psychotherapeutic care receive participation .</brief_summary>
	<brief_title>N-Acetylcysteine Adjunct DBT Treatment Self-Injurious Behavior BPD</brief_title>
	<detailed_description>Investigators withdraw study due poor subject compliance . After 3 consecutive participant either unable complete 6 week study drop DBT program , decision reach discontinue recruitment study terminate .</detailed_description>
	<mesh_term>Personality Disorders</mesh_term>
	<mesh_term>Borderline Personality Disorder</mesh_term>
	<mesh_term>Self-Injurious Behavior</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Borderline Personality Disorder , assess SCIDII A score 10 great Self Harm Inventory ( SHI ) time evaluation Ability give inform consent agreement engage reliable form birth control ( woman ) primary diagnosis psychotic disorder active substance abuse dependence unstable medical condition History intolerance/allergic reaction NAcetylcysteine pregnancy , breastfeeding , intent become pregnant study Inability understand English Cognitive Impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Borderline Personality Disorder ( BPD )</keyword>
	<keyword>Dialectical Behavioral Therapy ( DBT )</keyword>
	<keyword>glutamate</keyword>
	<keyword>N-Acetylcysteine</keyword>
	<keyword>Borderline Personality Disorder Self-Injurious Behavior</keyword>
</DOC>